Co. Uses RNA Editing as Treatment for Rare Disease

Research Report
  ()
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report
  ()
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report
  ()
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Opportunity for Investors Found in Psychedelics Space

Research Report
  ()
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Tags:  Psychedelics

US Biotech Firm Keeps Growing Revenue

Research Report
  ()
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.
Tags:  TechnologyHealthcare Services

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report
  ()
Argenx SE has "several upcoming catalysts," noted a Wedbush report.
Tags:  Special SituationsBiotechnology / Pharmaceuticals

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report
  ()
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World

  ()
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.
Tags:  Life Sciences Tools & DiagnosticsTechnologyHealthcare Services

Dermatology Co.'s Target Price Much Higher Than Current

Research Report
  ()
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report
  ()
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Expert Investing Ideas

"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–André Uddin, Research Capital Corporation


"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


"AGN's current valuation is favorable from a risk-reward standpoint."

–André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report
  ()
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

New Drug Shown To Help Patients With Desmoid Tumors

Research Report
  ()
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Price Target on US Biopharma Co. Boosted by $15

Research Report
  ()
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.
Tags:  Biotechnology / Pharmaceuticals

Several Trials of Co.'s Fluid Pump To Read Out This Year

Research Report
  ()
Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report.
Tags:  Medical Devices

Biotech Co.'s Target Six Times Current Price

Research Report
  ()
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.
Tags:  Psychedelics